Eli Lilly & Co. said it plans to begin commercial sales of its Covid-19 monoclonal antibody treatment to states, hospitals and other healthcare providers this month, as the federal government’s supply of the drug is nearly depleted.

The move marks a shift away from the way Lilly’s drug and most other Covid-19 treatments and vaccines have been distributed in the U.S. It will likely be the first test of whether the vaccines and treatments would remain accessible if shifted to a commercial market.

This post first appeared on wsj.com

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Elon Musk Explores Raising Up to $3 Billion to Help Pay Off Twitter Debt

WSJ News Exclusive Tech Billionaire has held talks with investors about selling…

How the U.S. plans to run diplomacy in Afghanistan from afar

WASHINGTON — The U.S. says it will remain intimately engaged in diplomacy…

Texas House committee recommends Attorney General Ken Paxton be impeached

A Texas House committee on Thursday unanimously voted to recommend that state…

Who Is China’s New No. 2? A Business Pragmatist or a Party Loyalist?

Xi Jinping’s new right-hand man, Li Qiang, has shown two sides to…